Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$0.72 ▼ -0.02
(-2.92%)
MKT CAP: $12.7M • VOL: 26.4K
52W L $1 52W H $2
IRIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-01-03 | FY 2024
FILED 2024-12-28 | FY 2023
FILED 2023-12-30 |
|---|---|---|---|
| Revenue (Total Sales) | $52.7M | $48.7M | $51.9M |
| YoY Revenue Growth % | +8.2% | -6.2% | — |
| Gross Profit | $19.2M | $19.5M | — |
| Gross Margin % | 36.5% | 40.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.6M | -$8.3M | -$10.0M |
| Operating Margin % | -4.9% | -17.1% | -19.3% |
| Net Income (GAAP) | -$4.4M | -$8.9M | -$9.6M |
| EBITDA (Normalized) | -$2.5M | -$8.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$2.1M | -$7.3M | -$6.7M |
| Capital Expenditures (CapEx) | $143.0K | $13.0K | — |
| Free Cash Flow (FCF) | -$2.3M | -$7.3M | -$6.7M |
| FCF Margin % | -4.3% | -15.0% | -13.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.0M | $2.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.9M | $2.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRIX.